Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.

ABSTRACT:

Importance

Some patients treated with nirmatrelvir-ritonavir have experienced rebound of COVID-19 infections and symptoms; however, data are scarce on whether viral rebound also occurs in patients with COVID-19 receiving or not receiving molnupiravir.

Objective

To examine the incidence of viral rebound in patients with COVID-19 who were treated with the oral antiviral agents nirmatrelvir-ritonavir and molnupiravir.

Design, setting, and participants

This cohort study identified 41 255 patients with COVID-19 who were hospitalized from January 1, 2022, to March 31, 2022, in Hong Kong and assessed 12 629 patients with serial cycle threshold (Ct) values measured. Patients were followed up until the occurrence of the clinical end point of interest, death, date of data retri

SUBMITTER: Wong GL 

PROVIDER: S-EPMC9856258 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature